# A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis

> **NCT04858659** · PHASE3 · UNKNOWN · sponsor: **PMG Pharm Co., Ltd** · enrollment: 354 (estimated)

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **DRUG:** PK101
- **DRUG:** PK101-002
- **DRUG:** PK101 placebo
- **DRUG:** PK101-002 placebo

## Key facts

- **NCT ID:** NCT04858659
- **Lead sponsor:** PMG Pharm Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-20
- **Primary completion:** 2022-03-15
- **Final completion:** 2022-03-15
- **Target enrollment:** 354 (ESTIMATED)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858659, "A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04858659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*